BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10322156)

  • 21. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
    Rice J; Buchan S; Stevenson FK
    J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
    Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
    Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes.
    Lu J; Celis E
    Cancer Res; 2000 Sep; 60(18):5223-7. PubMed ID: 11016651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes.
    Johnston JV; Malacko AR; Mizuno MT; McGowan P; Hellström I; Hellström KE; Marquardt H; Chen L
    J Exp Med; 1996 Mar; 183(3):791-800. PubMed ID: 8642283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
    Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
    Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: differential immunogenicity of Melan-A27-35 and Melan-A26-35.
    Chen Q; Jackson H; Cebon J; Gibbs P; Davis ID; Trapani JA
    Melanoma Res; 2000 Feb; 10(1):16-25. PubMed ID: 10711636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
    Davila E; Celis E
    J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction.
    Miconnet I; Coste I; Beermann F; Haeuw JF; Cerottini JC; Bonnefoy JY; Romero P; Renno T
    J Immunol; 2001 Apr; 166(7):4612-9. PubMed ID: 11254719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination.
    Chambers B; Grufman P; Fredriksson V; Andersson K; Roseboom M; Laban S; Camps M; Wolpert EZ; Wiertz EJ; Offringa R; Ljunggren HG; van Hall T
    Cancer Res; 2007 Sep; 67(18):8450-5. PubMed ID: 17875682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen.
    Lu J; Celis E
    Cancer Res; 2002 Oct; 62(20):5807-12. PubMed ID: 12384542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
    Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
    Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
    Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
    Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytes.
    Pinilla C; Rubio-Godoy V; Dutoit V; Guillaume P; Simon R; Zhao Y; Houghten RA; Cerottini JC; Romero P; Valmori D
    Cancer Res; 2001 Jul; 61(13):5153-60. PubMed ID: 11431354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes.
    Tamura M; Nishizaka S; Maeda Y; Ito M; Harashima N; Harada M; Shichijo S; Itoh K
    Jpn J Cancer Res; 2001 Jul; 92(7):762-7. PubMed ID: 11473727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mimotopes of tumor-associated T-cell epitopes for cancer vaccines determined with combinatorial peptide libraries.
    Sherev T; Wiesmüller KH; Walden P
    Mol Biotechnol; 2003 Sep; 25(1):53-61. PubMed ID: 13679635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy.
    Ozaki Y; Kontani K; Teramoto K; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Asai T; Ohkubo I
    Biochem Biophys Res Commun; 2004 May; 317(4):1089-95. PubMed ID: 15094380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Identification of a novel HLA-A2-restrictive CTL epitope of an ovary cancer-associated antigen OVA66].
    Jin S; Wang Y; Wang SJ; Zhang HZ; Li MX; Chen Y; Ge HL
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Mar; 21(2):233-6, 242. PubMed ID: 15766414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.